(i) administering a soluble TD antigen to which a humoral immune reaction is to be suppressed; and

(ii) administering an amount of a gp39 (CD40 ligand) antagonist selected from the group consisting of an anti-gp39 antibody, fragment thereof that binds gp39, soluble CD40, soluble CD40 fusion, in an amount effective to provide for prolonged humoral immune suppression to said soluble TD antigen, wherein prolonged humoral immune suppression means that antibody production remains suppressed after the anti-gp39 antibody has been cleared from the subject.

45. The method of Claim 44, wherein the soluble TD antigen is an allergen.

46. The method of Claim 44, wherein the soluble TD antigen is a protein.

47. The method of Claim 44, wherein the gp39 antagonist is an anti-gp39 antibody or fragment thereof.

48. The method of Claim 44, wherein the gp39 antagonist is soluble CD40 or CD40 fusion protein.

Sub B3 49. The method of Claim 47, wherein said anti-gp39 antibody is an anti-human gp39 antibody.

50. The method of Claim 44, which further comprises administering an IL-4 inhibitor.

Sub B4 51. The method of Claim 47, wherein the anti-gp39 antibody is a humanized antibody.

52. The method of Claim 47, wherein the antibody comprises human constant regions and non-human variable regions.

53. The method of Claim 44, which is used to treat an allergic disorder.

54. The method of Claim 50, wherein said IL-4 inhibitor is an anti-IL-4 antibody.

55. The method of Claim 54, which is used to treat an allergic disorder.--